Why You Shouldn't Forget This Biotech Despite Sell Signal

Résumé détaillé
On the most recent earnings call, CEO Jan Mikkelsen said the company plans to expand beyond just rare endocrine diseases. The post Why You Shouldn't Forget This Biotech Despite…
Ascendis Pharma (ASND) triggered the 7% sell rule on Friday as shares sold off alongside the broader market. This is a sign that investors who bought the breakout on Nov. 13 should be out of the stock. But given the Danish drugmaker's strong earnings growth and IBD ratings, this one is still worth watching. While many stocks are trading below…
Début de l'article, extrait de Investor's Business Daily. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.investors.com)